Key Takeaways BMY will co-develop BioNTech's BNT327, targeting solid tumors with a $3.5B investment through 2028. About $1.5B in IPR&D expense likely hit Q2, weighing on BMY's bottom-line results. BMY faces revenue declines from generics, Eliquis pricing, and lowered 2025-2026 EPS estimates. Last month, Bristol Myers Squibb (BMY) announced a strategic collaboration agreement with BioNTech (BNTX) for the global co-development and co-commercialization of the latter’s investigational bispecific antibody BNT3 ...